Cutaneous leishmaniasis
CL · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Cutaneous leishmaniasis, from sandfly-transmitted Leishmania species, causes chronic skin ulcers that may self-heal but scar, with risk of mucosal spread (New World species). Treatment choice depends on species, lesion number/site and host.
Red flags
- Mucosal involvement (nasal/oropharyngeal - New World)
- Extensive/disfiguring facial lesions
- Immunosuppression with disseminated disease
- Antimonial cardiotoxicity (QT prolongation)
- Secondary bacterial sepsis
Assessment
Differential diagnosis
- Chronic bacterial/fungal skin ulcer
- Cutaneous tuberculosis / atypical mycobacteria
- Skin malignancy (SCC/BCC)
- Sporotrichosis
- Tropical ulcer / pyoderma
Investigations
- Skin scraping/slit-skin smear and tissue for microscopy (amastigotes)
- PCR for species identification
- Culture (specialised)
- Travel history for Old World vs New World species
- Assess for mucosal involvement (New World)
- Biopsy to exclude malignancy if atypical
Management
- Take exposure history and localise/count lesions
- Confirm with microscopy and species-level PCR (guides mucosal risk and therapy)
- Assess whether local or systemic therapy is appropriate
- For simple Old World lesions, consider local therapy or observation if self-healing expected
- Use systemic therapy for complex, multiple, facial, or New World (mucosal-risk) disease
- Choose agent by species and local resistance patterns
- Monitor for drug toxicity (cardiac, renal, pancreatic with antimonials)
- Treat and prevent secondary bacterial infection
- Follow lesions to healing and watch for mucosal spread
- Provide wound care and scar management
- Counsel on sandfly avoidance
- Specialist tropical medicine input for complex cases
Drugs & doses
Liposomal amphotericin B (e.g. 3 mg/kg IV on days 1-5, 10 - species-dependent regimens)
Pentavalent antimony (sodium stibogluconate) 20 mg/kg/day IV/IM for 20 days (where used)
Miltefosine 2.5 mg/kg/day PO (max 150 mg/day) for 28 days
Intralesional antimony or cryotherapy/thermotherapy for simple Old World lesions
Disposition
Outpatient tropical medicine/dermatology; admit for systemic therapy if toxic agents or severe disease.
Complications & pitfalls
- Mucocutaneous leishmaniasis (destructive)
- Disfiguring scarring
- Secondary bacterial infection
- Drug toxicity (cardiac, renal, pancreatic)
- Relapse/chronicity in immunosuppression
Exam pearls
- Species identification drives therapy and mucosal-risk assessment
- Many Old World lesions self-heal - weigh treatment toxicity against benefit
- New World species carry mucocutaneous risk - lower threshold for systemic therapy
- Miltefosine is teratogenic - ensure contraception
- Monitor ECG and biochemistry with pentavalent antimonials
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.